La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Intercept Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Intercept Pharmaceuticals' Il CEO è Jerry Durso, nominato in Jan2021, e ha un mandato di 2.42 anni. la retribuzione annua totale è $ 4.46M, composta da 16% di stipendio e 84% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di MX$ 10.62M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 9.1 anni.

Informazioni chiave

Jerry Durso

Amministratore delegato

US$4.5m

Compenso totale

Percentuale dello stipendio del CEO	16.0%
Mandato del CEO	2.4yrs
Proprietà del CEO	0.1%
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	9.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jerry Durso rispetto agli utili di Intercept Pharmaceuticals?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2023	n/a	n/a	-US$173m
Dec 31 2022	US$4m	US$715k	-US$175m
Sep 30 2022	n/a	n/a	-US$202m
Jun 30 2022	n/a	n/a	-US$115m
Mar 31 2022	n/a	n/a	-US$120m
Dec 31 2021	US$8m	US$691k	-US$136m
Sep 30 2021	n/a	n/a	-US$144m
Jun 30 2021	n/a	n/a	-US$193m
Mar 31 2021	n/a	n/a	-US$231m
Dec 31 2020	US$4m	US$600k	-US$273m
Sep 30 2020	n/a	n/a	-US$321m
Jun 30 2020	n/a	n/a	-US$339m
Mar 31 2020	n/a	n/a	-US$347m
Dec 31 2019	US$4m	US$573k	-US$345m
Sep 30 2019	n/a	n/a	-US$335m
Jun 30 2019	n/a	n/a	-US$314m
Mar 31 2019	n/a	n/a	-US$318m
Dec 31 2018	US$3m	US$541k	-US$309m
Sep 30 2018	n/a	n/a	-US$333m
Jun 30 2018	n/a	n/a	-US$341m
Mar 31 2018	n/a	n/a	-US$352m
Dec 31 2017	US$4m	US$441k	-US$360m

Compensazione vs Mercato: La retribuzione totale di Jerry ($USD 4.46M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 442.02K ).

Compensazione vs guadagni: La retribuzione di Jerry è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jerry Durso (55 yo)

2.4yrs

Mandato

US$4,455,463

Compensazione

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jerome Durso	President	2.4yrs	US$4.46m	0.12% $ 10.6m
Andrew Saik	Chief Financial Officer	2yrs	US$1.39m	0.036% $ 3.1m
Jared Freedberg	General Counsel	2.3yrs	US$1.31m	0.14% $ 11.9m
Linda Richardson	Executive VP & Chief Commercial Officer	2.3yrs	US$1.34m	0.040% $ 3.4m
M. Berrey	President of Research & Development and Chief Medical Officer	2yrs	US$1.61m	0.054% $ 4.6m
Rocco Venezia	Chief Accounting Officer & Treasurer	2.3yrs	US$856.23k	0.061% $ 5.2m
Nareg Sagherian	Executive Director of Global Investor Relations	1.5yrs	Nessun dato	Nessun dato
David Ford	Chief Human Resources Officer	6.1yrs	US$1.91m	0.060% $ 5.1m
Mark Pruzanski	Founder	2.4yrs	US$6.43m	1.48% $ 126.8m
Paul Nitschmann	Senior Vice President of Regulatory Affairs	no data	Nessun dato	Nessun dato
Kathleen Munster	Chief Quality Officer & SVP of Technical Operations	less than a year	Nessun dato	Nessun dato
Michael Blash	Senior Vice President of Corporate Affairs	less than a year	Nessun dato	Nessun dato

2.3yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di ICPT * è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jerome Durso	President	2.1yrs	US$4.46m	0.12% $ 10.6m
Mark Pruzanski	Founder	21.4yrs	US$6.43m	1.48% $ 126.8m
Daniel Bradbury	Independent Director	6.9yrs	US$327.39k	0.056% $ 4.8m
Glenn Sblendorio	Independent Director	9.3yrs	US$332.39k	0.056% $ 4.8m
Luca Benatti	Independent Director	8.9yrs	US$327.39k	0.061% $ 5.2m
Srinivas Akkaraju	Independent Director	10.7yrs	US$317.39k	0.091% $ 7.8m
Gino Santini	Lead Independent Director	7.6yrs	US$337.39k	0.057% $ 4.8m
Paolo Fundaro	Independent Chairman of the Board	17.1yrs	US$342.39k	0.086% $ 7.3m
Alan Hofmann	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Scott Friedman	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Massimo Pinzani	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Aldo Roda	Member of the Scientific Advisory Board	no data	Nessun dato	Nessun dato

9.1yrs

Durata media

58.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ICPT * sono considerati esperti (durata media dell'incarico 9.1 anni).

Intercept Pharmaceuticals Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Recent updates

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media